Bausch Health Companies Inc.: Constipation trials

The registry lists 26 Constipation studies with Bausch Health Companies Inc. as lead sponsor. 1 are open to participants now and 18 have results posted.

Phase 1 2Phase 2 10Phase 3 11Phase 4 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FCRecruitingNCT07723924Phase 2
• An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic ConstipationCompletedNCT03120520Phase 2Results posted
• Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)CompletedNCT02493452Phase 3Results posted
• 12-Week Study of Plecanatide for CIC (The National CIC3 Study)CompletedNCT02122471Phase 3Results posted
• 12-Week Study of Plecanatide for CIC (The CIC3 Study)CompletedNCT01982240Phase 3Results posted
• Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)CompletedNCT01919697Phase 3Results posted
• The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)CompletedNCT01722318Phase 2Results posted
• The Plecanatide Chronic Idiopathic Constipation (CIC) StudyCompletedNCT01429987Phase 2/3Results posted
• Compassionate Use Study of MethylnaltrexoneCompletedNCT01368562Not applicableResults posted
• A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant PainCompletedNCT01186770Phase 3Results posted
• SP-304 Dose Ranging Study in Patients With Chronic Idiopathic ConstipationCompletedNCT01053962Phase 2Results posted
• Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-ConstipationCompletedNCT00936884Phase 3Results posted
• Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced ConstipationCompletedNCT00804141Phase 3Results posted
• Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced IllnessCompletedNCT00672477Phase 4Results posted
• Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced IllnessCompletedNCT00672139Phase 4Results posted
• Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic ProceduresCompletedNCT00640146Phase 2Results posted
• Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant PainCompletedNCT00605644Phase 2Results posted
• Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant PainCompletedNCT00547586Phase 2Results posted
• Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant PainCompletedNCT00529087Phase 3Results posted
• A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®CompletedNCT03551873
• Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)CompletedNCT01983306Phase 2
• Double-Blind, Double-Dummy, 2-Period Crossover of a 20-Minute Versus a 4-hour IV of MOA-728 in Stable Methadone SubjectsCompletedNCT00444158Phase 1
• Study of Methylnaltrexone (MNTX) for the Relief of ConstipationCompletedNCT00402038Phase 3
• A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness PatientsCompletedNCT00401362Phase 3
• Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant PainCompletedNCT00366431Phase 2
• Study Evaluating the Safety of MOA-728 Administered Orally to Healthy SubjectsCompletedNCT00311350Phase 1